Pulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients

Obeagu, E. I.; Babar, Q.; Vincent, C. C. N.; Okafor, C. J.; Eze, R.; Chijioke, U. O.; Ibekwe, A. M.; Uduchi, I. O.

Severe Acute Respiratory Syndrome Coronavirus 2 is a new type of coronavirus that can cause Coronavirus Disease 2019 (Covid-19) and is associated with an increased risk of thrombosis-related pulmonary embolism. Globally, doctors have revised their management strategies for suspected and confirmed PD in patients with Coronavirus disease (Covid-19) in 2019. Choosing the right drug and the right dose requires consideration of potential comorbidities, which can be explained by the direct and indirect pathological consequences of Covid-19, complement activation, cytokine release, endothelial dysfunction, and the interaction between different types of blood cells. Discuss the pathophysiological events, therapeutic mortality strategies, risk factors and clinical management of patients with Covid-19 pulmonary embolism.